nodes	percent_of_prediction	percent_of_DWPC	metapath
Tapentadol—Weight decreased—Bleomycin—lymphatic system cancer	0.00533	0.00533	CcSEcCtD
Tapentadol—Confusional state—Teniposide—lymphatic system cancer	0.00524	0.00524	CcSEcCtD
Tapentadol—Oedema—Teniposide—lymphatic system cancer	0.0052	0.0052	CcSEcCtD
Tapentadol—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.0052	0.0052	CcSEcCtD
Tapentadol—Infection—Teniposide—lymphatic system cancer	0.00517	0.00517	CcSEcCtD
Tapentadol—Agitation—Fludarabine—lymphatic system cancer	0.00515	0.00515	CcSEcCtD
Tapentadol—Aspartate aminotransferase increased—Vincristine—lymphatic system cancer	0.00512	0.00512	CcSEcCtD
Tapentadol—Tachycardia—Teniposide—lymphatic system cancer	0.00508	0.00508	CcSEcCtD
Tapentadol—Hyperhidrosis—Teniposide—lymphatic system cancer	0.00503	0.00503	CcSEcCtD
Tapentadol—Pruritus—Mechlorethamine—lymphatic system cancer	0.00499	0.00499	CcSEcCtD
Tapentadol—Aspartate aminotransferase increased—Mitoxantrone—lymphatic system cancer	0.00498	0.00498	CcSEcCtD
Tapentadol—Cough—Fludarabine—lymphatic system cancer	0.00489	0.00489	CcSEcCtD
Tapentadol—Alanine aminotransferase increased—Mitoxantrone—lymphatic system cancer	0.00488	0.00488	CcSEcCtD
Tapentadol—Hypotension—Teniposide—lymphatic system cancer	0.00486	0.00486	CcSEcCtD
Tapentadol—Convulsion—Fludarabine—lymphatic system cancer	0.00485	0.00485	CcSEcCtD
Tapentadol—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00483	0.00483	CcSEcCtD
Tapentadol—Arthralgia—Fludarabine—lymphatic system cancer	0.00477	0.00477	CcSEcCtD
Tapentadol—Hypoaesthesia—Bleomycin—lymphatic system cancer	0.00469	0.00469	CcSEcCtD
Tapentadol—Dyspnoea—Teniposide—lymphatic system cancer	0.00464	0.00464	CcSEcCtD
Tapentadol—Confusional state—Fludarabine—lymphatic system cancer	0.00461	0.00461	CcSEcCtD
Tapentadol—Depression—Carmustine—lymphatic system cancer	0.00457	0.00457	CcSEcCtD
Tapentadol—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.00457	0.00457	CcSEcCtD
Tapentadol—Oedema—Fludarabine—lymphatic system cancer	0.00457	0.00457	CcSEcCtD
Tapentadol—Infection—Fludarabine—lymphatic system cancer	0.00454	0.00454	CcSEcCtD
Tapentadol—Erectile dysfunction—Vincristine—lymphatic system cancer	0.00452	0.00452	CcSEcCtD
Tapentadol—Decreased appetite—Teniposide—lymphatic system cancer	0.00452	0.00452	CcSEcCtD
Tapentadol—Vomiting—Mechlorethamine—lymphatic system cancer	0.00449	0.00449	CcSEcCtD
Tapentadol—Nervous system disorder—Fludarabine—lymphatic system cancer	0.00448	0.00448	CcSEcCtD
Tapentadol—Urinary tract infection—Carmustine—lymphatic system cancer	0.00446	0.00446	CcSEcCtD
Tapentadol—Rash—Mechlorethamine—lymphatic system cancer	0.00445	0.00445	CcSEcCtD
Tapentadol—Upper respiratory tract infection—Mitoxantrone—lymphatic system cancer	0.00445	0.00445	CcSEcCtD
Tapentadol—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00444	0.00444	CcSEcCtD
Tapentadol—Weight decreased—Vincristine—lymphatic system cancer	0.00444	0.00444	CcSEcCtD
Tapentadol—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.00442	0.00442	CcSEcCtD
Tapentadol—Erectile dysfunction—Mitoxantrone—lymphatic system cancer	0.00441	0.00441	CcSEcCtD
Tapentadol—Depression—Vincristine—lymphatic system cancer	0.00437	0.00437	CcSEcCtD
Tapentadol—Weight decreased—Mitoxantrone—lymphatic system cancer	0.00433	0.00433	CcSEcCtD
Tapentadol—Feeling abnormal—Teniposide—lymphatic system cancer	0.00429	0.00429	CcSEcCtD
Tapentadol—Chills—Bleomycin—lymphatic system cancer	0.00423	0.00423	CcSEcCtD
Tapentadol—Nausea—Mechlorethamine—lymphatic system cancer	0.00419	0.00419	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00417	0.00417	CcSEcCtD
Tapentadol—Urinary tract infection—Mitoxantrone—lymphatic system cancer	0.00415	0.00415	CcSEcCtD
Tapentadol—Urticaria—Teniposide—lymphatic system cancer	0.00413	0.00413	CcSEcCtD
Tapentadol—Paraesthesia—Fludarabine—lymphatic system cancer	0.00411	0.00411	CcSEcCtD
Tapentadol—Hallucination—Carmustine—lymphatic system cancer	0.0041	0.0041	CcSEcCtD
Tapentadol—Hypoaesthesia—Carmustine—lymphatic system cancer	0.0041	0.0041	CcSEcCtD
Tapentadol—Dyspnoea—Fludarabine—lymphatic system cancer	0.00408	0.00408	CcSEcCtD
Tapentadol—Connective tissue disorder—Carmustine—lymphatic system cancer	0.00405	0.00405	CcSEcCtD
Tapentadol—Dyspepsia—Fludarabine—lymphatic system cancer	0.00402	0.00402	CcSEcCtD
Tapentadol—Dysarthria—Methotrexate—lymphatic system cancer	0.00402	0.00402	CcSEcCtD
Tapentadol—Decreased appetite—Fludarabine—lymphatic system cancer	0.00397	0.00397	CcSEcCtD
Tapentadol—Visual impairment—Carmustine—lymphatic system cancer	0.00397	0.00397	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00395	0.00395	CcSEcCtD
Tapentadol—Fatigue—Fludarabine—lymphatic system cancer	0.00394	0.00394	CcSEcCtD
Tapentadol—Hallucination—Vincristine—lymphatic system cancer	0.00391	0.00391	CcSEcCtD
Tapentadol—Hypoaesthesia—Vincristine—lymphatic system cancer	0.00391	0.00391	CcSEcCtD
Tapentadol—Constipation—Fludarabine—lymphatic system cancer	0.00391	0.00391	CcSEcCtD
Tapentadol—Bradycardia—Mitoxantrone—lymphatic system cancer	0.0039	0.0039	CcSEcCtD
Tapentadol—Urinary tract disorder—Vincristine—lymphatic system cancer	0.00388	0.00388	CcSEcCtD
Tapentadol—Connective tissue disorder—Vincristine—lymphatic system cancer	0.00386	0.00386	CcSEcCtD
Tapentadol—Urethral disorder—Vincristine—lymphatic system cancer	0.00385	0.00385	CcSEcCtD
Tapentadol—Eye disorder—Carmustine—lymphatic system cancer	0.00385	0.00385	CcSEcCtD
Tapentadol—Hypersensitivity—Teniposide—lymphatic system cancer	0.00383	0.00383	CcSEcCtD
Tapentadol—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00377	0.00377	CcSEcCtD
Tapentadol—Asthenia—Teniposide—lymphatic system cancer	0.00373	0.00373	CcSEcCtD
Tapentadol—Pruritus—Teniposide—lymphatic system cancer	0.00368	0.00368	CcSEcCtD
Tapentadol—Depressed level of consciousness—Methotrexate—lymphatic system cancer	0.00367	0.00367	CcSEcCtD
Tapentadol—Cardiac disorder—Vincristine—lymphatic system cancer	0.00365	0.00365	CcSEcCtD
Tapentadol—Mental disorder—Carmustine—lymphatic system cancer	0.00361	0.00361	CcSEcCtD
Tapentadol—Malnutrition—Carmustine—lymphatic system cancer	0.00359	0.00359	CcSEcCtD
Tapentadol—Cough—Bleomycin—lymphatic system cancer	0.00358	0.00358	CcSEcCtD
Tapentadol—Angiopathy—Vincristine—lymphatic system cancer	0.00357	0.00357	CcSEcCtD
Tapentadol—Diarrhoea—Teniposide—lymphatic system cancer	0.00356	0.00356	CcSEcCtD
Tapentadol—Mediastinal disorder—Vincristine—lymphatic system cancer	0.00354	0.00354	CcSEcCtD
Tapentadol—Mental disorder—Vincristine—lymphatic system cancer	0.00344	0.00344	CcSEcCtD
Tapentadol—Chills—Mitoxantrone—lymphatic system cancer	0.00344	0.00344	CcSEcCtD
Tapentadol—Confusional state—Bleomycin—lymphatic system cancer	0.00338	0.00338	CcSEcCtD
Tapentadol—Vision blurred—Carmustine—lymphatic system cancer	0.00338	0.00338	CcSEcCtD
Tapentadol—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00337	0.00337	CcSEcCtD
Tapentadol—Tremor—Carmustine—lymphatic system cancer	0.00336	0.00336	CcSEcCtD
Tapentadol—Oedema—Bleomycin—lymphatic system cancer	0.00335	0.00335	CcSEcCtD
Tapentadol—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00335	0.00335	CcSEcCtD
Tapentadol—Infection—Bleomycin—lymphatic system cancer	0.00333	0.00333	CcSEcCtD
Tapentadol—Vomiting—Teniposide—lymphatic system cancer	0.00331	0.00331	CcSEcCtD
Tapentadol—Agitation—Carmustine—lymphatic system cancer	0.00329	0.00329	CcSEcCtD
Tapentadol—Asthenia—Fludarabine—lymphatic system cancer	0.00328	0.00328	CcSEcCtD
Tapentadol—Rash—Teniposide—lymphatic system cancer	0.00328	0.00328	CcSEcCtD
Tapentadol—Dermatitis—Teniposide—lymphatic system cancer	0.00328	0.00328	CcSEcCtD
Tapentadol—Headache—Teniposide—lymphatic system cancer	0.00326	0.00326	CcSEcCtD
Tapentadol—Pruritus—Fludarabine—lymphatic system cancer	0.00323	0.00323	CcSEcCtD
Tapentadol—Agitation—Vincristine—lymphatic system cancer	0.00314	0.00314	CcSEcCtD
Tapentadol—Vision blurred—Mitoxantrone—lymphatic system cancer	0.00314	0.00314	CcSEcCtD
Tapentadol—Hypotension—Bleomycin—lymphatic system cancer	0.00313	0.00313	CcSEcCtD
Tapentadol—Diarrhoea—Fludarabine—lymphatic system cancer	0.00313	0.00313	CcSEcCtD
Tapentadol—Convulsion—Carmustine—lymphatic system cancer	0.00311	0.00311	CcSEcCtD
Tapentadol—Nausea—Teniposide—lymphatic system cancer	0.00309	0.00309	CcSEcCtD
Tapentadol—Vertigo—Vincristine—lymphatic system cancer	0.00307	0.00307	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00305	0.00305	CcSEcCtD
Tapentadol—Anxiety—Carmustine—lymphatic system cancer	0.00304	0.00304	CcSEcCtD
Tapentadol—Paraesthesia—Bleomycin—lymphatic system cancer	0.00301	0.00301	CcSEcCtD
Tapentadol—Dyspnoea—Bleomycin—lymphatic system cancer	0.00299	0.00299	CcSEcCtD
Tapentadol—Convulsion—Vincristine—lymphatic system cancer	0.00297	0.00297	CcSEcCtD
Tapentadol—Confusional state—Carmustine—lymphatic system cancer	0.00295	0.00295	CcSEcCtD
Tapentadol—Oedema—Carmustine—lymphatic system cancer	0.00293	0.00293	CcSEcCtD
Tapentadol—Decreased appetite—Bleomycin—lymphatic system cancer	0.00291	0.00291	CcSEcCtD
Tapentadol—Visual disturbance—Methotrexate—lymphatic system cancer	0.00291	0.00291	CcSEcCtD
Tapentadol—Cough—Mitoxantrone—lymphatic system cancer	0.00291	0.00291	CcSEcCtD
Tapentadol—Infection—Carmustine—lymphatic system cancer	0.00291	0.00291	CcSEcCtD
Tapentadol—Vomiting—Fludarabine—lymphatic system cancer	0.00291	0.00291	CcSEcCtD
Tapentadol—Convulsion—Mitoxantrone—lymphatic system cancer	0.00289	0.00289	CcSEcCtD
Tapentadol—Rash—Fludarabine—lymphatic system cancer	0.00288	0.00288	CcSEcCtD
Tapentadol—Dermatitis—Fludarabine—lymphatic system cancer	0.00288	0.00288	CcSEcCtD
Tapentadol—Headache—Fludarabine—lymphatic system cancer	0.00286	0.00286	CcSEcCtD
Tapentadol—Tachycardia—Carmustine—lymphatic system cancer	0.00286	0.00286	CcSEcCtD
Tapentadol—Arthralgia—Mitoxantrone—lymphatic system cancer	0.00284	0.00284	CcSEcCtD
Tapentadol—Anxiety—Mitoxantrone—lymphatic system cancer	0.00283	0.00283	CcSEcCtD
Tapentadol—Lethargy—Methotrexate—lymphatic system cancer	0.00281	0.00281	CcSEcCtD
Tapentadol—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00279	0.00279	CcSEcCtD
Tapentadol—Oedema—Vincristine—lymphatic system cancer	0.00279	0.00279	CcSEcCtD
Tapentadol—Infection—Vincristine—lymphatic system cancer	0.00277	0.00277	CcSEcCtD
Tapentadol—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00276	0.00276	CcSEcCtD
Tapentadol—Osteoarthritis—Methotrexate—lymphatic system cancer	0.00276	0.00276	CcSEcCtD
Tapentadol—Confusional state—Mitoxantrone—lymphatic system cancer	0.00274	0.00274	CcSEcCtD
Tapentadol—Nervous system disorder—Vincristine—lymphatic system cancer	0.00274	0.00274	CcSEcCtD
Tapentadol—Hypotension—Carmustine—lymphatic system cancer	0.00273	0.00273	CcSEcCtD
Tapentadol—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00272	0.00272	CcSEcCtD
Tapentadol—Oedema—Mitoxantrone—lymphatic system cancer	0.00272	0.00272	CcSEcCtD
Tapentadol—Nausea—Fludarabine—lymphatic system cancer	0.00272	0.00272	CcSEcCtD
Tapentadol—Infection—Mitoxantrone—lymphatic system cancer	0.0027	0.0027	CcSEcCtD
Tapentadol—Hyperhidrosis—Vincristine—lymphatic system cancer	0.0027	0.0027	CcSEcCtD
Tapentadol—Shock—Mitoxantrone—lymphatic system cancer	0.00268	0.00268	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00267	0.00267	CcSEcCtD
Tapentadol—Urticaria—Bleomycin—lymphatic system cancer	0.00266	0.00266	CcSEcCtD
Tapentadol—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00265	0.00265	CcSEcCtD
Tapentadol—Insomnia—Carmustine—lymphatic system cancer	0.00265	0.00265	CcSEcCtD
Tapentadol—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00264	0.00264	CcSEcCtD
Tapentadol—Irritability—Methotrexate—lymphatic system cancer	0.00263	0.00263	CcSEcCtD
Tapentadol—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00263	0.00263	CcSEcCtD
Tapentadol—Paraesthesia—Carmustine—lymphatic system cancer	0.00263	0.00263	CcSEcCtD
Tapentadol—Hypotension—Vincristine—lymphatic system cancer	0.00261	0.00261	CcSEcCtD
Tapentadol—Dyspnoea—Carmustine—lymphatic system cancer	0.00261	0.00261	CcSEcCtD
Tapentadol—Somnolence—Carmustine—lymphatic system cancer	0.0026	0.0026	CcSEcCtD
Tapentadol—Ataxia—Methotrexate—lymphatic system cancer	0.00259	0.00259	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00254	0.00254	CcSEcCtD
Tapentadol—Decreased appetite—Carmustine—lymphatic system cancer	0.00254	0.00254	CcSEcCtD
Tapentadol—Hypotension—Mitoxantrone—lymphatic system cancer	0.00254	0.00254	CcSEcCtD
Tapentadol—Insomnia—Vincristine—lymphatic system cancer	0.00253	0.00253	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00253	0.00253	CcSEcCtD
Tapentadol—Paraesthesia—Vincristine—lymphatic system cancer	0.00251	0.00251	CcSEcCtD
Tapentadol—Constipation—Carmustine—lymphatic system cancer	0.0025	0.0025	CcSEcCtD
Tapentadol—Breast disorder—Methotrexate—lymphatic system cancer	0.00249	0.00249	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00248	0.00248	CcSEcCtD
Tapentadol—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00247	0.00247	CcSEcCtD
Tapentadol—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00244	0.00244	CcSEcCtD
Tapentadol—Decreased appetite—Vincristine—lymphatic system cancer	0.00243	0.00243	CcSEcCtD
Tapentadol—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00243	0.00243	CcSEcCtD
Tapentadol—Somnolence—Mitoxantrone—lymphatic system cancer	0.00242	0.00242	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00241	0.00241	CcSEcCtD
Tapentadol—Feeling abnormal—Carmustine—lymphatic system cancer	0.00241	0.00241	CcSEcCtD
Tapentadol—Fatigue—Vincristine—lymphatic system cancer	0.00241	0.00241	CcSEcCtD
Tapentadol—Asthenia—Bleomycin—lymphatic system cancer	0.0024	0.0024	CcSEcCtD
Tapentadol—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00239	0.00239	CcSEcCtD
Tapentadol—Constipation—Vincristine—lymphatic system cancer	0.00239	0.00239	CcSEcCtD
Tapentadol—Pruritus—Bleomycin—lymphatic system cancer	0.00237	0.00237	CcSEcCtD
Tapentadol—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00236	0.00236	CcSEcCtD
Tapentadol—Fatigue—Mitoxantrone—lymphatic system cancer	0.00235	0.00235	CcSEcCtD
Tapentadol—Constipation—Mitoxantrone—lymphatic system cancer	0.00233	0.00233	CcSEcCtD
Tapentadol—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.00228	0.00228	CcSEcCtD
Tapentadol—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00224	0.00224	CcSEcCtD
Tapentadol—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.00221	0.00221	CcSEcCtD
Tapentadol—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.00219	0.00219	CcSEcCtD
Tapentadol—Urticaria—Mitoxantrone—lymphatic system cancer	0.00216	0.00216	CcSEcCtD
Tapentadol—Hypersensitivity—Carmustine—lymphatic system cancer	0.00216	0.00216	CcSEcCtD
Tapentadol—Vomiting—Bleomycin—lymphatic system cancer	0.00213	0.00213	CcSEcCtD
Tapentadol—Infestation—Methotrexate—lymphatic system cancer	0.00212	0.00212	CcSEcCtD
Tapentadol—Infestation NOS—Methotrexate—lymphatic system cancer	0.00212	0.00212	CcSEcCtD
Tapentadol—Depression—Methotrexate—lymphatic system cancer	0.00212	0.00212	CcSEcCtD
Tapentadol—Rash—Bleomycin—lymphatic system cancer	0.00211	0.00211	CcSEcCtD
Tapentadol—Dermatitis—Bleomycin—lymphatic system cancer	0.00211	0.00211	CcSEcCtD
Tapentadol—Asthenia—Carmustine—lymphatic system cancer	0.0021	0.0021	CcSEcCtD
Tapentadol—Hypersensitivity—Vincristine—lymphatic system cancer	0.00206	0.00206	CcSEcCtD
Tapentadol—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.002	0.002	CcSEcCtD
Tapentadol—Asthenia—Vincristine—lymphatic system cancer	0.002	0.002	CcSEcCtD
Tapentadol—Diarrhoea—Carmustine—lymphatic system cancer	0.002	0.002	CcSEcCtD
Tapentadol—Nausea—Bleomycin—lymphatic system cancer	0.00199	0.00199	CcSEcCtD
Tapentadol—Asthenia—Mitoxantrone—lymphatic system cancer	0.00195	0.00195	CcSEcCtD
Tapentadol—Dizziness—Carmustine—lymphatic system cancer	0.00193	0.00193	CcSEcCtD
Tapentadol—Diarrhoea—Vincristine—lymphatic system cancer	0.00191	0.00191	CcSEcCtD
Tapentadol—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.00188	0.00188	CcSEcCtD
Tapentadol—Urethral disorder—Methotrexate—lymphatic system cancer	0.00187	0.00187	CcSEcCtD
Tapentadol—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00186	0.00186	CcSEcCtD
Tapentadol—Vomiting—Carmustine—lymphatic system cancer	0.00186	0.00186	CcSEcCtD
Tapentadol—Dizziness—Vincristine—lymphatic system cancer	0.00185	0.00185	CcSEcCtD
Tapentadol—Rash—Carmustine—lymphatic system cancer	0.00184	0.00184	CcSEcCtD
Tapentadol—Dermatitis—Carmustine—lymphatic system cancer	0.00184	0.00184	CcSEcCtD
Tapentadol—Visual impairment—Methotrexate—lymphatic system cancer	0.00184	0.00184	CcSEcCtD
Tapentadol—Headache—Carmustine—lymphatic system cancer	0.00183	0.00183	CcSEcCtD
Tapentadol—Eye disorder—Methotrexate—lymphatic system cancer	0.00178	0.00178	CcSEcCtD
Tapentadol—Vomiting—Vincristine—lymphatic system cancer	0.00178	0.00178	CcSEcCtD
Tapentadol—Cardiac disorder—Methotrexate—lymphatic system cancer	0.00177	0.00177	CcSEcCtD
Tapentadol—Rash—Vincristine—lymphatic system cancer	0.00176	0.00176	CcSEcCtD
Tapentadol—Dermatitis—Vincristine—lymphatic system cancer	0.00176	0.00176	CcSEcCtD
Tapentadol—Headache—Vincristine—lymphatic system cancer	0.00175	0.00175	CcSEcCtD
Tapentadol—Nausea—Carmustine—lymphatic system cancer	0.00174	0.00174	CcSEcCtD
Tapentadol—Angiopathy—Methotrexate—lymphatic system cancer	0.00173	0.00173	CcSEcCtD
Tapentadol—Vomiting—Mitoxantrone—lymphatic system cancer	0.00173	0.00173	CcSEcCtD
Tapentadol—Immune system disorder—Methotrexate—lymphatic system cancer	0.00172	0.00172	CcSEcCtD
Tapentadol—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.00172	0.00172	CcSEcCtD
Tapentadol—Rash—Mitoxantrone—lymphatic system cancer	0.00172	0.00172	CcSEcCtD
Tapentadol—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00171	0.00171	CcSEcCtD
Tapentadol—Chills—Methotrexate—lymphatic system cancer	0.00171	0.00171	CcSEcCtD
Tapentadol—Headache—Mitoxantrone—lymphatic system cancer	0.0017	0.0017	CcSEcCtD
Tapentadol—Mental disorder—Methotrexate—lymphatic system cancer	0.00167	0.00167	CcSEcCtD
Tapentadol—Malnutrition—Methotrexate—lymphatic system cancer	0.00166	0.00166	CcSEcCtD
Tapentadol—Nausea—Vincristine—lymphatic system cancer	0.00166	0.00166	CcSEcCtD
Tapentadol—Nausea—Mitoxantrone—lymphatic system cancer	0.00162	0.00162	CcSEcCtD
Tapentadol—Vision blurred—Methotrexate—lymphatic system cancer	0.00156	0.00156	CcSEcCtD
Tapentadol—Vertigo—Methotrexate—lymphatic system cancer	0.00149	0.00149	CcSEcCtD
Tapentadol—Cough—Methotrexate—lymphatic system cancer	0.00145	0.00145	CcSEcCtD
Tapentadol—Convulsion—Methotrexate—lymphatic system cancer	0.00144	0.00144	CcSEcCtD
Tapentadol—Arthralgia—Methotrexate—lymphatic system cancer	0.00141	0.00141	CcSEcCtD
Tapentadol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.0014	0.0014	CcSEcCtD
Tapentadol—Confusional state—Methotrexate—lymphatic system cancer	0.00137	0.00137	CcSEcCtD
Tapentadol—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.00136	0.00136	CcSEcCtD
Tapentadol—Infection—Methotrexate—lymphatic system cancer	0.00135	0.00135	CcSEcCtD
Tapentadol—Nervous system disorder—Methotrexate—lymphatic system cancer	0.00133	0.00133	CcSEcCtD
Tapentadol—Skin disorder—Methotrexate—lymphatic system cancer	0.00132	0.00132	CcSEcCtD
Tapentadol—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.00131	0.00131	CcSEcCtD
Tapentadol—Hypotension—Methotrexate—lymphatic system cancer	0.00127	0.00127	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.00123	0.00123	CcSEcCtD
Tapentadol—Insomnia—Methotrexate—lymphatic system cancer	0.00123	0.00123	CcSEcCtD
Tapentadol—Paraesthesia—Methotrexate—lymphatic system cancer	0.00122	0.00122	CcSEcCtD
Tapentadol—Dyspnoea—Methotrexate—lymphatic system cancer	0.00121	0.00121	CcSEcCtD
Tapentadol—Somnolence—Methotrexate—lymphatic system cancer	0.0012	0.0012	CcSEcCtD
Tapentadol—Dyspepsia—Methotrexate—lymphatic system cancer	0.00119	0.00119	CcSEcCtD
Tapentadol—Decreased appetite—Methotrexate—lymphatic system cancer	0.00118	0.00118	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.00117	0.00117	CcSEcCtD
Tapentadol—Fatigue—Methotrexate—lymphatic system cancer	0.00117	0.00117	CcSEcCtD
Tapentadol—Feeling abnormal—Methotrexate—lymphatic system cancer	0.00112	0.00112	CcSEcCtD
Tapentadol—Urticaria—Methotrexate—lymphatic system cancer	0.00108	0.00108	CcSEcCtD
Tapentadol—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000998	0.000998	CcSEcCtD
Tapentadol—Asthenia—Methotrexate—lymphatic system cancer	0.000972	0.000972	CcSEcCtD
Tapentadol—Pruritus—Methotrexate—lymphatic system cancer	0.000959	0.000959	CcSEcCtD
Tapentadol—Diarrhoea—Methotrexate—lymphatic system cancer	0.000927	0.000927	CcSEcCtD
Tapentadol—Dizziness—Methotrexate—lymphatic system cancer	0.000896	0.000896	CcSEcCtD
Tapentadol—Vomiting—Methotrexate—lymphatic system cancer	0.000862	0.000862	CcSEcCtD
Tapentadol—Rash—Methotrexate—lymphatic system cancer	0.000854	0.000854	CcSEcCtD
Tapentadol—Dermatitis—Methotrexate—lymphatic system cancer	0.000854	0.000854	CcSEcCtD
Tapentadol—Headache—Methotrexate—lymphatic system cancer	0.000849	0.000849	CcSEcCtD
Tapentadol—Nausea—Methotrexate—lymphatic system cancer	0.000805	0.000805	CcSEcCtD
